Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
You may also be interested in...
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.